Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 4/20 | 0.40 |
| ▸ | ACACA | Q13085 | 3/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6221470 | 0.87 | CKS1B (0.43) | DRD2KMT2ACKS1BSKP1SKP2 | |
| SCHEMBL6221463 | 0.87 | CKS1B (0.43) | DRD2KMT2ACKS1BSKP1SKP2 | |
| SCHEMBL17114329 | 0.85 | KMT2A (0.48) | KMT2AOPRK1KDM4E | |
| SCHEMBL17114330 | 0.85 | KMT2A (0.48) | KMT2AOPRK1KDM4E | |
| SCHEMBL28805974 | 0.85 | DRD2 (0.43) | DRD2KMT2ACKS1BSKP1SKP2 | |
| SCHEMBL11024826 | 0.80 | DRD2 (0.45) | DRD2KMT2ACKS1BSKP1SKP2 | |
| SCHEMBL19088850 | 0.79 | EPHX1 (0.41) | DRD2KMT2AL3MBTL1 | |
| SCHEMBL19088851 | 0.79 | EPHX1 (0.41) | DRD2KMT2AL3MBTL1 | |
| SCHEMBL7390418 | 0.77 | LMNA (0.56) | DRD2CKS1BSKP1SKP2KDM4E | |
| SCHEMBL5462244 | 0.77 | LMNA (0.56) | DRD2CKS1BSKP1SKP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981957-B2 | Synthetic process | THE UNIVERSITY OF LIVERPOOL (GB) | 2018-05-29 | — | — | US | disclosed |
| US-9981957-B2 | Synthetic process | THE UNIVERSITY OF LIVERPOOL (GB) | 2018-05-29 | — | — | US | disclosed |
| US-20170107208-A1 | SYNTHETIC PROCESS | THE UNIVERSITY OF LIVERPOOL (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20170107208-A1 | SYNTHETIC PROCESS | THE UNIVERSITY OF LIVERPOOL (GB) | 2017-04-20 | — | — | US | disclosed |
| WO-2015145143-A1 | SYNTHETIC PROCESS | THE UNIVERSITY OF LIVERPOOL (GB) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107208-A1 | SYNTHETIC PROCESS | PIR, SRM, SMS | DRD2 168/4885KMT2A 1086/4885CKS1B 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.